Compare Stocks: IONS, ROIV, UTHR, and INCY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INCY Incyte	$122.85 +4.5%	$120.12	$89.25 ▼ $132.60	$25.04B	0.78	1.74 million shs	2.07 million shs
IONS Ionis Pharmaceuticals	$40.15 -0.7%	$48.22	$39.33 ▼ $86.74	$6.67B	0.43	2.67 million shs	3.89 million shs
ROIV Roivant Sciences	$38.23 +6.1%	$36.63	$19.61 ▼ $42.50	$27.61B	1.23	6.47 million shs	10.91 million shs
UTHR United Therapeutics	$608.49 +1.2%	$530.53	$432.53 ▼ $614.23	$26.10B	0.49	557,122 shs	908,530 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INCY Incyte	-2.04%	+0.85%	+1.99%	-1.84%	+15.77%
IONS Ionis Pharmaceuticals	-1.99%	-8.05%	-7.17%	-25.41%	-45.12%
ROIV Roivant Sciences	+0.42%	-1.37%	+0.90%	+4.16%	+83.88%
UTHR United Therapeutics	+0.87%	+1.71%	+11.01%	+15.79%	+37.08%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
INCY Incyte	$122.85 +4.5%	$120.12	$89.25 ▼ $132.60	$25.04B	0.78	1.74 million shs	2.07 million shs
IONS Ionis Pharmaceuticals	$40.15 -0.7%	$48.22	$39.33 ▼ $86.74	$6.67B	0.43	2.67 million shs	3.89 million shs
ROIV Roivant Sciences	$38.23 +6.1%	$36.63	$19.61 ▼ $42.50	$27.61B	1.23	6.47 million shs	10.91 million shs
UTHR United Therapeutics	$608.49 +1.2%	$530.53	$432.53 ▼ $614.23	$26.10B	0.49	557,122 shs	908,530 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
INCY Incyte	-2.04%	+0.85%	+1.99%	-1.84%	+15.77%
IONS Ionis Pharmaceuticals	-1.99%	-8.05%	-7.17%	-25.41%	-45.12%
ROIV Roivant Sciences	+0.42%	-1.37%	+0.90%	+4.16%	+83.88%
UTHR United Therapeutics	+0.87%	+1.71%	+11.01%	+15.79%	+37.08%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
INCY Incyte	2.44	Hold	$133.10	8.34% Upside
IONS Ionis Pharmaceuticals	2.78	Moderate Buy	$89.48	122.85% Upside
ROIV Roivant Sciences	2.79	Moderate Buy	$46.55	21.75% Upside
UTHR United Therapeutics	2.75	Moderate Buy	$674.00	10.77% Upside

Current Analyst Ratings Breakdown

Latest IONS, ROIV, UTHR, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
11/4/2026	UTHR United Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$720.00
11/4/2026	UTHR United Therapeutics	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$728.00 ➝ $768.00
11/2/2026	INCY Incyte	Sanford C. Bernstein Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Market Perform	$104.00 ➝ $108.00
10/30/2026	INCY Incyte	UBS Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$152.00
10/30/2026	INCY Incyte	Wells Fargo & Company Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Equal Weight	$128.00 ➝ $127.00
10/30/2026	INCY Incyte	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Sector Perform	$114.00 ➝ $117.00
10/30/2026	INCY Incyte	Barclays Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$139.00 ➝ $143.00
10/28/2026	ROIV Roivant Sciences	Citigroup Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$46.00 ➝ $56.00
10/28/2026	UTHR United Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$710.00 ➝ $695.00
10/27/2026	INCY Incyte	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Market Perform
10/27/2026	INCY Incyte	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Set Price Target		$152.00

(Data available from 11/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
INCY Incyte	$5.14B	4.87	$6.33 per share	19.42	$27.68 per share	4.44
IONS Ionis Pharmaceuticals	$944M	7.07	N/A	N/A	$3.02 per share	13.29
ROIV Roivant Sciences	$8.26M	3,343.13	N/A	N/A	$7.35 per share	5.20
UTHR United Therapeutics	$3.18B	8.20	$33.67 per share	18.07	$164.81 per share	3.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
INCY Incyte	$1.29B	$1.88	65.35	15.93	4.50	6.71%	7.92%	6.12%	N/A
IONS Ionis Pharmaceuticals	-$381.39M	-$3.46	N/A	N/A	N/A	-64.76%	-111.08%	-17.41%	11/9/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	21.77	19.75	4.32	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest IONS, ROIV, UTHR, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q3 2026	IONS Ionis Pharmaceuticals	-$1.22	N/A	N/A	N/A	$181.57 million	N/A
11/9/2026	Q2 2027	ROIV Roivant Sciences	-$0.3666	N/A	N/A	N/A	$4.15 million	N/A
11/4/2026	Q3 2026	UTHR United Therapeutics	$6.01	$5.71	-$0.30	$5.71	$781.14 million	$832.50 million
10/29/2026	Q3 2026	INCY Incyte	-$3.93	-$3.60	+$0.33	-$3.86	$1.46 billion	$1.56 billion
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
INCY Incyte	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
INCY Incyte	N/A	3.84	3.75
IONS Ionis Pharmaceuticals	3.07	7.89	7.73
ROIV Roivant Sciences	N/A	16.72	16.72
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
INCY Incyte	96.97%
IONS Ionis Pharmaceuticals	93.86%
ROIV Roivant Sciences	64.76%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
INCY Incyte	16.20%
IONS Ionis Pharmaceuticals	1.81%
ROIV Roivant Sciences	8.80%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
INCY Incyte	2,844	203.83 million	170.81 million	Optionable
IONS Ionis Pharmaceuticals	1,402	166.18 million	163.18 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

IONS, ROIV, UTHR, and INCY Headlines

Recent News About These Companies

United Therapeutics (NASDAQ:UTHR) Posts Quarterly Earnings Results, Misses Expectations By $0.30 EPS

54 minutes ago | marketbeat.com

United Therapeutics Corporation (UTHR) Q3 2026 Earnings Call Transcript

3 hours ago | seekingalpha.com

BTIG Research Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) Stock

4 hours ago | marketbeat.com

United Therapeutics (UTHR) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

November 4 at 10:31 AM | zacks.com

United Therapeutics Announces Buydown of Ralinepag Royalty

November 4 at 8:53 AM | biospace.comB

United Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026

November 4 at 8:53 AM | marketscreener.comM

Earnings Flash (UTHR) United Therapeutics Reports Q3 Revenue $832.5M, vs. FactSet Est of $781.1M

November 4 at 8:53 AM | marketscreener.comM

United Therapeutics Q3 Net Income Falls, Revenue Rises

November 4 at 8:53 AM | finance.yahoo.com

United Therapeutics buys out Pfizer royalties linked to lung disease therapy

November 4 at 8:53 AM | seekingalpha.com

United Therapeutics (NASDAQ: UTHR) beats Q3 2026 sales expectations, stock soars

November 4 at 8:53 AM | msn.com

United Therapeutics (UTHR) Q3 Earnings Miss Estimates

November 4 at 8:36 AM | zacks.com

United Therapeutics Corporation Reports Third Quarter 2026 Financial Results

November 4 at 7:00 AM | businesswire.com

United Therapeutics Corp

November 4 at 3:51 AM | 247wallst.com

United Therapeutics (NASDAQ:UTHR) Stock: Insider Martine Rothblatt Sells 9,500 Shares

November 3 at 5:07 PM | marketbeat.com

United Therapeutics (UTHR) Expected to Release Quarterly Earnings on Wednesday

November 3 at 4:46 AM | americanbankingnews.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $5,700,855.00 in Stock

November 3 at 4:07 AM | insidertrades.com

United Therapeutics (NASDAQ: UTHR) CEO Rothblatt sells $5.65 million of option shares

November 3 at 3:13 AM | americanbankingnews.com

United Therapeutics (UTHR) to report earnings tomorrow: here is what to expect

November 3 at 3:10 AM | financialcontent.comF

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

November 2 at 5:07 PM | marketbeat.com

United Therapeutics Corporation $UTHR Stock Purchased by Profund Advisors LLC

November 2 at 7:40 AM | marketbeat.com

SGIOY vs. UTHR: Which Stock Is the Better Value Option?

October 30, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

IONS, ROIV, UTHR, and INCY Company Descriptions

Incyte NASDAQ:INCY

$122.85 +5.26 (+4.47%)

Closing price 04:00 PM Eastern

Extended Trading

$122.92 +0.07 (+0.05%)

As of 05:03 PM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Ionis Pharmaceuticals NASDAQ:IONS

$40.15 -0.27 (-0.67%)

Closing price 04:00 PM Eastern

Extended Trading

$40.32 +0.17 (+0.42%)

As of 04:48 PM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Roivant Sciences NASDAQ:ROIV

$38.23 +2.19 (+6.08%)

Closing price 04:00 PM Eastern

Extended Trading

$37.41 -0.82 (-2.16%)

As of 05:03 PM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

United Therapeutics NASDAQ:UTHR

$608.49 +7.17 (+1.19%)

Closing price 04:00 PM Eastern

Extended Trading

$608.71 +0.22 (+0.04%)

As of 05:03 PM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, ROIV, UTHR, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, ROIV, UTHR, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, ROIV, UTHR, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, ROIV, UTHR, and INCY Company Descriptions

Incyte NASDAQ:INCY

Ionis Pharmaceuticals NASDAQ:IONS

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IONS, ROIV, UTHR, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IONS, ROIV, UTHR, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IONS, ROIV, UTHR, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

IONS, ROIV, UTHR, and INCY Company Descriptions

Incyte NASDAQ:INCY

Ionis Pharmaceuticals NASDAQ:IONS

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools